Current Report Filing (8-k)
August 30 2019 - 4:20PM
Edgar (US Regulatory)
0001551152
false
Common Stock, $0.01 Par Value
ABBV
0001551152
2019-08-26
2019-08-27
0001551152
us-gaap:CommonStockMember
exch:XCHI
2019-08-26
2019-08-27
0001551152
us-gaap:CommonStockMember
exch:XNYS
2019-08-26
2019-08-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Common Stock, $0.01 Par Value
|
ABBV
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 30, 2019 (August 27, 2019)
ABBVIE INC.
(Exact Name of Registrant as Specified in
its Charter)
Delaware
|
|
001-35565
|
|
32-0375147
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (847) 932-7900
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, $0.01 Par Value
|
|
ABBV
|
|
New
York Stock Exchange
Chicago Stock Exchange
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item 1.01. Entry into a Material Definitive Agreement.
Amended and Restated Revolving Credit Agreement
On August 27, 2019 (the “Effective
Date”), AbbVie Inc. (“AbbVie”) entered into an amended and restated revolving credit agreement (the “Amended
and Restated Revolving Credit Agreement”) among AbbVie, as borrower, the lenders and other parties party thereto and JPMorgan
Chase Bank, N.A., as administrative agent (in such capacity, the “Agent”), providing for the amendment and restatement,
effective as of the Effective Date, of that certain revolving credit agreement, dated as of August 31, 2018, among AbbVie, as borrower,
the lenders and other parties party thereto and the Agent. The Amended and Restated Revolving Credit Agreement (i) increases the
unsecured revolving credit facility commitments from $3.0 billion to $4.0 billion and (ii) extends the maturity date of the facility
from August 31, 2023 to August 27, 2024.
The foregoing summary of the Amended and
Restated Revolving Credit Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full
text of the Amended and Restated Revolving Credit Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K
and incorporated herein by reference.
Item 2.03. Creation of a Direct
Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
On August 27, 2019, AbbVie entered into
the Amended and Restated Revolving Credit Agreement as described under Item 1.01 above. The description of the Amended and
Restated Revolving Credit Agreement set forth in Item 1.01 above is hereby incorporated by reference.
Item 9.01. Financial Statements
and Exhibits.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ABBVIE INC.
|
|
|
Date: August 30, 2019
|
By:
|
/s/ Robert A. Michael
|
|
|
Robert A. Michael
|
|
|
Executive Vice President, Chief Financial Officer
|
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024